Regulus Therapeutics

Aug 08, 2023

•

Jun 30, 2023

Regulus Therapeutics Q2 2023 Earnings Report

Regulus Therapeutics reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Takeaways

Regulus Therapeutics reported a net loss of $7.0 million for the second quarter of 2023, with research and development expenses at $5.0 million and general and administrative expenses at $2.3 million. The company's cash and cash equivalents totaled $37.3 million as of June 30, 2023, expected to fund operations into mid-2024. The company's RGLS8429 Phase 1b MAD study progresses with the first patient dosed in the second cohort.

First patient was dosed in the second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429.

R&D Day to discuss the ADPKD program will be held on Wednesday, September 6th.

Preston S. Klassen, M.D. was appointed as President and Head of Research & Development.

Curtis A. Monnig, Ph.D. was appointed as Vice President of CMC.

Research and development expenses

$4.98M

General and administrative expenses

$2.34M

Cash and Equivalents